Phaseline

Companies › Beletalent (Zhuhai) Pharmaceutical

Beletalent (Zhuhai) Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
TNTL–Phase 3Non-Proliferative Diabetic RetinopathyDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06817265TNTLPhase 3Non-Proliferative Diabetic RetinopathyOphthalmologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Cloudbreak Therapeutics Omikron Italia S.r.l. Viridian Therapeutics Aurion Biotech Smilebiotek Zhuhai

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.